Survival | |||
Study | Topotecan group | PLD group | p value |
Median survival (by week) | |||
Gordon 2004a | 59.7 | 62.7 | |
median survival‐platium‐sensitive(by week) | |||
Gordon 2004a | 70.1 | 107.9 | |
median survival‐platium‐resistant(by week) | |||
Gordon 2004a | 41.3 | 35.6 | 0.455 |
Survival | |||
Study | Topotecan group | PLD group | p value |
Median survival (by week) | |||
Gordon 2004a | 59.7 | 62.7 | |
median survival‐platium‐sensitive(by week) | |||
Gordon 2004a | 70.1 | 107.9 | |
median survival‐platium‐resistant(by week) | |||
Gordon 2004a | 41.3 | 35.6 | 0.455 |